Table 2 Multivariate of the clinicopathological factors for progression-free survival and overall survival

Age (years)

0.380

 ≤ 65

Reference

 > 65

0.855 (0.602–1.213)

Gender

0.606

 Female

Reference

 Male

1.096 (0.774–1.551)

BMI (kg/m²)

0.599

0.613

 BMI < 18.5

Reference

Reference

 18.5 ≤ BMI < 25

0.756 (0.345–1.658)

0.486

0.836 (0.339–2.062)

0.697

 BMI ≥ 25

0.680 (0.305–1.518)

0.347

0.680 (0.251–1.799)

0.428

Tumour location

< 0.001

< 0.001

 Non-gastric

Reference

Reference

 Gastric

0.523 (0.372–0.736)

0.409 (0.250–0.669)

Tumour size (cm)

0.002

0.018

 ≤ 10

Reference

Reference

 > 10

1.841 (1.255–2.700)

1.889 (1.113–3.206)

Mitotic index (per 50 HPF)

0.005

0.115

 0–5

Reference

Reference

 6–10

0.891 (0.582–1.365)

0.595

1.103 (0.609–1.995)

0.747

 > 10

1.752 (1.186–2.589)

0.005

1.749 (1.017–3.007)

0.043

Surgical approach

0.209

0.482

 Laparoscopy

Reference

Reference

 Open

1.413 (0.824–2.426)

1.355 (0.581–3.159)

Multi-organ involved

0.005

0.173

 No

Reference

Reference

 Yes

1.868 (1.208–2.889)

1.473 (0.844–2.570)

Blood transfusion

0.865

0.655

 No

Reference

Reference

 Yes

1.032 (0.721–1.476)

1.118 (0.686–1.821)

Postoperative imatinib

< 0.001

< 0.001

 No

Reference

Reference

 Yes

0.493 (0.350–0.696)

0.405 (0.246–0.669)

NPS group

< 0.001

< 0.001

 0

Reference

Reference

 1

4.622 (1.807–11.820)

0.001

1.945 (0.668–5.660)

0.222

 2

12.770 (4.932–33.059)

< 0.001

5.535 (1.923–15.929)

0.002